Abstract
A new computational approach (PEP) is presented for the structure-based design of linear polymeric ligands consisting of any type of amino acid. Ligands are grown from a seed by iteratively adding amino acids to the growing construct. The search in chemical space is performed by a build-up approach which employs all of the residues of a user-defined library. At every growing step, a genetic algorithm is used for conformational optimization of the last added monomer inside the binding site of a rigid target protein. The binding energy with electrostatic solvation is evaluated to select sequences for further growing. PEP is tested on the peptide substrate binding site of the insulin receptor tyrosine kinase and farnesyltransferase. In both test cases, the peptides designed by PEP correspond to the sequence motifs of known substrates. For tyrosine kinase, tyrosine residues are suggested at position P and P+2. While the tyrosine at P is in agreement with the experimental data, the one at P+2 is a predict ion which awaits experimental validation. For farnesyltransferase, it is shown that electrostatic solvation is necessary for the correct design of peptidic inhibitors.
Keywords: PEP, Insulin receptor tyrosine kinase, farnesyltransferase
Combinatorial Chemistry & High Throughput Screening
Title: An Evolutionary Approach for Structure-based Design of Natural and Non-natural Peptidic Ligands
Volume: 4 Issue: 8
Author(s): Nicolas Budin, Shaheen Ahmed, Nicolas Majeux and Amedeo Caflisch
Affiliation:
Keywords: PEP, Insulin receptor tyrosine kinase, farnesyltransferase
Abstract: A new computational approach (PEP) is presented for the structure-based design of linear polymeric ligands consisting of any type of amino acid. Ligands are grown from a seed by iteratively adding amino acids to the growing construct. The search in chemical space is performed by a build-up approach which employs all of the residues of a user-defined library. At every growing step, a genetic algorithm is used for conformational optimization of the last added monomer inside the binding site of a rigid target protein. The binding energy with electrostatic solvation is evaluated to select sequences for further growing. PEP is tested on the peptide substrate binding site of the insulin receptor tyrosine kinase and farnesyltransferase. In both test cases, the peptides designed by PEP correspond to the sequence motifs of known substrates. For tyrosine kinase, tyrosine residues are suggested at position P and P+2. While the tyrosine at P is in agreement with the experimental data, the one at P+2 is a predict ion which awaits experimental validation. For farnesyltransferase, it is shown that electrostatic solvation is necessary for the correct design of peptidic inhibitors.
Export Options
About this article
Cite this article as:
Budin Nicolas, Ahmed Shaheen, Majeux Nicolas and Caflisch Amedeo, An Evolutionary Approach for Structure-based Design of Natural and Non-natural Peptidic Ligands, Combinatorial Chemistry & High Throughput Screening 2001; 4 (8) . https://dx.doi.org/10.2174/1386207013330652
DOI https://dx.doi.org/10.2174/1386207013330652 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Critical Appraisal of the Functional Evolution of P2Y12 Antagonists as Antiplatelet Drugs
Current Pharmaceutical Design Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Correlation Analysis of Capillary APOE, VEGF and eNOS Expression in Alzheimer Brains
Current Alzheimer Research The Role of Alpha-lipoic Acid Supplementation in the Prevention of Diabetes Complications: A Comprehensive Review of Clinical Trials
Current Diabetes Reviews Connexin-Made Channels as Pharmacological Targets
Current Pharmaceutical Design Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Concepts for Biologically Active Peptides
Current Pharmaceutical Design Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research
Current Topics in Medicinal Chemistry The Role of Aβ Peptides in Alzheimers Disease
Protein & Peptide Letters Female Infertility and Assisted Reproduction: Impact of Oxidative Stress-- An Update
Current Women`s Health Reviews Fibrates and Statins in the Treatment of Diabetic Retinopathy
Current Pharmaceutical Biotechnology Genetic Signatures in the Treatment of Stroke
Current Pharmaceutical Design Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Synaptic Plasticity, Dementia and Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Targeting T-Cell Adhesion Molecules for Drug Design
Current Pharmaceutical Design Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy
Current Stem Cell Research & Therapy Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update
Current Neuropharmacology Old and New Drug Targets in Diabetic Retinopathy: From Biochemical Changes to Inflammation and Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Lipid Management for the Prevention of Cardiovascular Disease
Current Pharmaceutical Design